Differentiation of CD8+ T Cells from Tumor-Invaded and Tumor-Free Lymph Nodes of Melanoma Patients: Role of Common γ-Chain Cytokines1
暂无分享,去创建一个
[1] F. Sallusto,et al. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. , 2003, Blood.
[2] Rustom Antia,et al. Lineage relationship and protective immunity of memory CD8 T cell subsets , 2003, Nature Immunology.
[3] M. Weekes,et al. Identification of Naive or Antigen-Experienced Human CD8+ T Cells by Expression of Costimulation and Chemokine Receptors: Analysis of the Human Cytomegalovirus-Specific CD8+ T Cell Response1 , 2002, The Journal of Immunology.
[4] F. Marincola,et al. Functional Heterogeneity of Vaccine-Induced CD8+ T Cells1 , 2002, The Journal of Immunology.
[5] M. Caligiuri,et al. Interleukin-2 and interleukin-15: immunotherapy for cancer. , 2002, Cytokine & growth factor reviews.
[6] D. Richman,et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections , 2002, Nature Medicine.
[7] J. Karbach,et al. Peptide‐specific CD8+ T‐cell evolution in vivo: Response to peptide vaccination with Melan‐A/MART‐1 , 2002, International journal of cancer.
[8] D. Schadendorf,et al. Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. , 2002, Cancer research.
[9] D. Speiser,et al. In vivo activation of melanoma‐specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus‐specific T cells , 2002, European journal of immunology.
[10] F. Sallusto,et al. Cytokine-driven proliferation and differentiation of human naïve, central memory and effector memory CD4+ T cells. , 2003, Pathologie-biologie.
[11] F. Sallusto,et al. Cytokine-driven Proliferation and Differentiation of Human Naive, Central Memory, and Effector Memory CD4+ T Cells , 2001, The Journal of experimental medicine.
[12] J. Lieberman,et al. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. , 2001, The Journal of clinical investigation.
[13] Martin F. Mihm,et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Steven A. Rosenberg,et al. Progress in human tumour immunology and immunotherapy , 2001, Nature.
[15] S. Riddell,et al. In vivo tracking of tumor-specific T cells. , 2001, Current opinion in immunology.
[16] A. Houghton,et al. Immunity against cancer: lessons learned from melanoma. , 2001, Current opinion in immunology.
[17] S. Rowland-Jones,et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes , 2001, Nature.
[18] A. Harris,et al. A Shift in the Phenotype of Melan-A-Specific CTL Identifies Melanoma Patients with an Active Tumor-Specific Immune Response1 , 2000, The Journal of Immunology.
[19] A. Gaggero,et al. IL-15/IL-15Rα intracellular trafficking in human melanoma cells and signal transduction through the IL-15Rα , 2000, Oncogene.
[20] F. Sallusto,et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.
[21] V. Cerundolo,et al. An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions , 1999, The Journal of experimental medicine.
[22] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[23] J. Sprent,et al. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. , 1998, Immunity.
[24] P. Romero,et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. , 1998, Journal of immunology.
[25] D. Jäger,et al. Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes , 1998, The Journal of experimental medicine.
[26] M. Rep,et al. Phenotypic and Functional Separation of Memory and Effector Human CD8+ T Cells , 1997, The Journal of experimental medicine.
[27] R. Dummer,et al. Interleukin‐10 is a growth factor for human melanoma cells and down‐regulates HLA class‐I, HLA class‐II and ICAM‐1 molecules , 1997, International journal of cancer.
[28] R. Kerbel,et al. Endogenous interleukin 6 can function as an in vivo growth- stimulatory factor for advanced-stage human melanoma cells. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] J. Sprent,et al. Induction of Bystander T Cell Proliferation by Viruses and Type I Interferon in Vivo , 1996, Science.
[30] A. Sette,et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.
[31] P. Coulie,et al. A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3 , 1994, European journal of immunology.
[32] K. Sakaguchi,et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.
[33] R. Moots,et al. Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA‐A2 in its recognition by cytotoxic T lymphocytes , 1992, European journal of immunology.
[34] S. Ferrone,et al. Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants. , 1985, Journal of immunology.
[35] S. Ferrone,et al. The monoclonal antibody CR11-351 discriminates HLA-A2 variants identified by T cells , 2004, Immunogenetics.
[36] Susan M. Kaech,et al. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. , 2002 .